Bupivacaine Injection Recalled Due to Lack of Sterility Assurance
Nephron Sterile Compounding Center is recalling 6900 syringes of Bupivacaine HCl Injection nationwide due to lack of sterility assurance. No illnesses or injuries have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall for an injectable pharmaceutical product lacking sterility assurance. Although no illnesses or injuries have been reported, injectable products with compromised sterility represent a direct risk of harm to patients who would receive the medication.
Plain-English summary
Nephron Sterile Compounding Center LLC, a 503B outsourcing facility, is recalling 0.125% Bupivacaine HCl Injection, USP (1.25 mg/mL) in pre-filled syringes due to lack of assurance of sterility.
The recalled product was distributed nationwide. It consists of pre-filled 50 mL syringes in cartons of 5, packaged 6 cartons per case (NDC 69374-970-50). Approximately 6900 syringes have been recalled across eight lot numbers—BH2001A through BH2010A—with expiration dates ranging from July 15, 2022 to October 19, 2022.
No illnesses or injuries have been reported in connection with this recall. Customers and healthcare providers with questions about the affected product should contact Nephron Sterile Compounding Center LLC or the U.S. Food and Drug Administration.
The recalled product
- Product
- 0.125% Bupivacaine HCl Injection, USP, 62.5 mg/50 mL (1.25 mg/mL) syringes, packaged in 5 x 50 mL Pre-Filled Syringes per carton, 6 x 5 Syringe Carton per case, Rx Only, Nephron 503B outsourcing facility, 4500 12th St. Ext., West Columbia, SC 29172, NDC: 69374-970-50
- Manufacturer
- Nephron Sterile Compounding Center LLC
- Hazard
- lack-of-sterility
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (16)
- Lots: BH2001A
- Exp. 7/15/2022
- BH2002A
- Exp. 8/7/2022
- BH2004A
- Exp. 8/22/2022
- BH2005A
- Exp. 9/2/2022
- BH2006A
- Exp. 9/14/2022
- BH2007A
- Exp. 9/29/2022
- BH2008A
- Exp. 10/3/2022
- BH2010A
- Exp. 10/19/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27